Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 48

1.

MEK inhibitors enhance therapeutic response towards ATRA in NF1 associated malignant peripheral nerve sheath tumors (MPNST) in-vitro.

Fischer-Huchzermeyer S, Dombrowski A, Wilke G, Stahn V, Streubel A, Mautner VF, Harder A.

PLoS One. 2017 Nov 13;12(11):e0187700. doi: 10.1371/journal.pone.0187700. eCollection 2017.

2.

Emerging genotype-phenotype relationships in patients with large NF1 deletions.

Kehrer-Sawatzki H, Mautner VF, Cooper DN.

Hum Genet. 2017 Apr;136(4):349-376. doi: 10.1007/s00439-017-1766-y. Epub 2017 Feb 17. Review.

3.

Non-optic glioma in adults and children with neurofibromatosis 1.

Sellmer L, Farschtschi S, Marangoni M, Heran MK, Birch P, Wenzel R, Friedman JM, Mautner VF.

Orphanet J Rare Dis. 2017 Feb 15;12(1):34. doi: 10.1186/s13023-017-0588-2.

4.

The molecular pathogenesis of schwannomatosis, a paradigm for the co-involvement of multiple tumour suppressor genes in tumorigenesis.

Kehrer-Sawatzki H, Farschtschi S, Mautner VF, Cooper DN.

Hum Genet. 2017 Feb;136(2):129-148. doi: 10.1007/s00439-016-1753-8. Epub 2016 Dec 5. Review.

5.

Current whole-body MRI applications in the neurofibromatoses: NF1, NF2, and schwannomatosis.

Ahlawat S, Fayad LM, Khan MS, Bredella MA, Harris GJ, Evans DG, Farschtschi S, Jacobs MA, Chhabra A, Salamon JM, Wenzel R, Mautner VF, Dombi E, Cai W, Plotkin SR, Blakeley JO; Whole Body MRI Committee for the REiNS International Collaboration; REiNS International Collaboration Members 2016.

Neurology. 2016 Aug 16;87(7 Suppl 1):S31-9. doi: 10.1212/WNL.0000000000002929.

6.

Effector T cell subclasses associate with tumor burden in neurofibromatosis type 1 patients.

Farschtschi S, Park SJ, Sawitzki B, Oh SJ, Kluwe L, Mautner VF, Kurtz A.

Cancer Immunol Immunother. 2016 Sep;65(9):1113-21. doi: 10.1007/s00262-016-1871-0. Epub 2016 Jul 23.

7.

The importance of nerve microenvironment for schwannoma development.

Schulz A, Büttner R, Hagel C, Baader SL, Kluwe L, Salamon J, Mautner VF, Mindos T, Parkinson DB, Gehlhausen JR, Clapp DW, Morrison H.

Acta Neuropathol. 2016 Aug;132(2):289-307. doi: 10.1007/s00401-016-1583-8. Epub 2016 May 28.

8.

Unilateral gynaecomastia in a 16-month-old boy with neurofibromatosis type 1 - case report and brief review of the literature.

Friedrich RE, Hagel C, Mautner VF.

GMS Interdiscip Plast Reconstr Surg DGPW. 2015 Dec 3;4:Doc11. doi: 10.3205/iprs000070. eCollection 2015.

9.

Impairment of Procedural Learning and Motor Intracortical Inhibition in Neurofibromatosis Type 1 Patients.

Zimerman M, Wessel MJ, Timmermann JE, Granström S, Gerloff C, Mautner VF, Hummel FC.

EBioMedicine. 2015 Sep 1;2(10):1430-7. doi: 10.1016/j.ebiom.2015.08.036. eCollection 2015 Oct.

10.

Nerve Sheath Tumors in Neurofibromatosis Type 1: Assessment of Whole-Body Metabolic Tumor Burden Using F-18-FDG PET/CT.

Salamon J, Papp L, Tóth Z, Laqmani A, Apostolova I, Adam G, Mautner VF, Derlin T.

PLoS One. 2015 Dec 1;10(12):e0143305. doi: 10.1371/journal.pone.0143305. eCollection 2015.

11.

Keratinocytic epidermal nevus syndrome with Schwann cell proliferation, lipomatous tumour and mosaic KRAS mutation.

Farschtschi S, Mautner VF, Hollants S, Hagel C, Spaepen M, Schulte C, Legius E, Brems H.

BMC Med Genet. 2015 Feb 10;16:6. doi: 10.1186/s12881-015-0146-5.

12.

Preclinical assessment of the anticancer drug response of plexiform neurofibroma tissue using primary cultures.

Jiang W, Mautner VF, Friedrich RE, Kluwe L.

J Clin Neurol. 2015 Apr;11(2):172-7. doi: 10.3988/jcn.2015.11.2.172.

13.

Perfusion single photon emission computed tomography in a mouse model of neurofibromatosis type 1: towards a biomarker of neurologic deficits.

Apostolova I, Niedzielska D, Derlin T, Koziolek EJ, Amthauer H, Salmen B, Pahnke J, Brenner W, Mautner VF, Buchert R.

J Cereb Blood Flow Metab. 2015 Aug;35(8):1304-12. doi: 10.1038/jcbfm.2015.43. Epub 2015 Mar 18.

14.

Double NF1 inactivation affects adrenocortical function in NF1Prx1 mice and a human patient.

Kobus K, Hartl D, Ott CE, Osswald M, Huebner A, von der Hagen M, Emmerich D, Kühnisch J, Morreau H, Hes FJ, Mautner VF, Harder A, Tinschert S, Mundlos S, Kolanczyk M.

PLoS One. 2015 Mar 16;10(3):e0119030. doi: 10.1371/journal.pone.0119030. eCollection 2015.

15.

Nilotinib is more potent than imatinib for treating plexiform neurofibroma in vitro and in vivo.

Wei J, Freytag M, Schober Y, Nockher WA, Mautner VF, Friedrich RE, Manley PW, Kluwe L, Kurtz A.

PLoS One. 2014 Oct 23;9(10):e107760. doi: 10.1371/journal.pone.0107760. eCollection 2014.

16.

Somatic neurofibromatosis type 1 (NF1) inactivation events in cutaneous neurofibromas of a single NF1 patient.

Emmerich D, Zemojtel T, Hecht J, Krawitz P, Spielmann M, Kühnisch J, Kobus K, Osswald M, Heinrich V, Berlien P, Müller U, Mautner VF, Wimmer K, Robinson PN, Vingron M, Tinschert S, Mundlos S, Kolanczyk M.

Eur J Hum Genet. 2015 Jun;23(6):870-3. doi: 10.1038/ejhg.2014.210. Epub 2014 Oct 8.

17.

SVA retrotransposon insertion-associated deletion represents a novel mutational mechanism underlying large genomic copy number changes with non-recurrent breakpoints.

Vogt J, Bengesser K, Claes KB, Wimmer K, Mautner VF, van Minkelen R, Legius E, Brems H, Upadhyaya M, Högel J, Lazaro C, Rosenbaum T, Bammert S, Messiaen L, Cooper DN, Kehrer-Sawatzki H.

Genome Biol. 2014 Jun 2;15(6):R80. doi: 10.1186/gb-2014-15-6-r80.

18.

Treatment of orthotopic malignant peripheral nerve sheath tumors with oncolytic herpes simplex virus.

Antoszczyk S, Spyra M, Mautner VF, Kurtz A, Stemmer-Rachamimov AO, Martuza RL, Rabkin SD.

Neuro Oncol. 2014 Aug;16(8):1057-66. doi: 10.1093/neuonc/not317. Epub 2014 Jan 26.

19.

Neuronal merlin influences ERBB2 receptor expression on Schwann cells through neuregulin 1 type III signalling.

Schulz A, Kyselyova A, Baader SL, Jung MJ, Zoch A, Mautner VF, Hagel C, Morrison H.

Brain. 2014 Feb;137(Pt 2):420-32. doi: 10.1093/brain/awt327. Epub 2013 Dec 5.

20.

Lovastatin improves impaired synaptic plasticity and phasic alertness in patients with neurofibromatosis type 1.

Mainberger F, Jung NH, Zenker M, Wahlländer U, Freudenberg L, Langer S, Berweck S, Winkler T, Straube A, Heinen F, Granström S, Mautner VF, Lidzba K, Mall V.

BMC Neurol. 2013 Oct 2;13:131. doi: 10.1186/1471-2377-13-131.

Supplemental Content

Loading ...
Support Center